209 related articles for article (PubMed ID: 30742064)
1. Protein Kinase N1 control of androgen-responsive serum response factor action provides rationale for novel prostate cancer treatment strategy.
Venkadakrishnan VB; DePriest AD; Kumari S; Senapati D; Ben-Salem S; Su Y; Mudduluru G; Hu Q; Cortes E; Pop E; Mohler JL; Azabdaftari G; Attwood K; Shah RB; Jamieson C; Dehm SM; Magi-Galluzzi C; Klein E; Sharifi N; Liu S; Heemers HV
Oncogene; 2019 Jun; 38(23):4496-4511. PubMed ID: 30742064
[TBL] [Abstract][Full Text] [Related]
2. Identification of a RhoA- and SRF-dependent mechanism of androgen action that is associated with prostate cancer progression.
Heemers HV
Curr Drug Targets; 2013 Apr; 14(4):481-9. PubMed ID: 23469924
[TBL] [Abstract][Full Text] [Related]
3. RhoA as a mediator of clinically relevant androgen action in prostate cancer cells.
Schmidt LJ; Duncan K; Yadav N; Regan KM; Verone AR; Lohse CM; Pop EA; Attwood K; Wilding G; Mohler JL; Sebo TJ; Tindall DJ; Heemers HV
Mol Endocrinol; 2012 May; 26(5):716-35. PubMed ID: 22456196
[TBL] [Abstract][Full Text] [Related]
4. Androgen-responsive serum response factor target genes regulate prostate cancer cell migration.
Verone AR; Duncan K; Godoy A; Yadav N; Bakin A; Koochekpour S; Jin JP; Heemers HV
Carcinogenesis; 2013 Aug; 34(8):1737-46. PubMed ID: 23576568
[TBL] [Abstract][Full Text] [Related]
5. Relationship between serum response factor and androgen receptor in prostate cancer.
Prencipe M; O'Neill A; O'Hurley G; Nguyen LK; Fabre A; Bjartell A; Gallagher WM; Morrissey C; Kay EW; Watson RW
Prostate; 2015 Nov; 75(15):1704-17. PubMed ID: 26250344
[TBL] [Abstract][Full Text] [Related]
6. Targeting androgen receptor action for prostate cancer treatment: does the post-receptor level provide novel opportunities?
Heemers HV
Int J Biol Sci; 2014; 10(6):576-87. PubMed ID: 24948870
[TBL] [Abstract][Full Text] [Related]
7. Androgen induction of the androgen receptor coactivator four and a half LIM domain protein-2: evidence for a role for serum response factor in prostate cancer.
Heemers HV; Regan KM; Dehm SM; Tindall DJ
Cancer Res; 2007 Nov; 67(21):10592-9. PubMed ID: 17975004
[TBL] [Abstract][Full Text] [Related]
8. KAT8 Regulates Androgen Signaling in Prostate Cancer Cells.
Kim JY; Yu J; Abdulkadir SA; Chakravarti D
Mol Endocrinol; 2016 Aug; 30(8):925-36. PubMed ID: 27268279
[TBL] [Abstract][Full Text] [Related]
9. A comprehensive analysis of coregulator recruitment, androgen receptor function and gene expression in prostate cancer.
Liu S; Kumari S; Hu Q; Senapati D; Venkadakrishnan VB; Wang D; DePriest AD; Schlanger SE; Ben-Salem S; Valenzuela MM; Willard B; Mudambi S; Swetzig WM; Das GM; Shourideh M; Koochekpour S; Falzarano SM; Magi-Galluzzi C; Yadav N; Chen X; Lao C; Wang J; Billaud JN; Heemers HV
Elife; 2017 Aug; 6():. PubMed ID: 28826481
[TBL] [Abstract][Full Text] [Related]
10. Functional implications and therapeutic targeting of androgen response elements in prostate cancer.
Senapati D; Sharma V; Rath SK; Rai U; Panigrahi N
Biochimie; 2023 Nov; 214(Pt B):188-198. PubMed ID: 37460038
[TBL] [Abstract][Full Text] [Related]
11. Androgen Deprivation Therapy Potentiates the Efficacy of Vascular Targeted Photodynamic Therapy of Prostate Cancer Xenografts.
Kim K; Watson PA; Lebdai S; Jebiwott S; Somma AJ; La Rosa S; Mehta D; Murray KS; Lilja H; Ulmert D; Monette S; Scherz A; Coleman JA
Clin Cancer Res; 2018 May; 24(10):2408-2416. PubMed ID: 29463549
[No Abstract] [Full Text] [Related]
12. Src controls castration recurrence of CWR22 prostate cancer xenografts.
Su B; Gillard B; Gao L; Eng KH; Gelman IH
Cancer Med; 2013 Dec; 2(6):784-92. PubMed ID: 24403252
[TBL] [Abstract][Full Text] [Related]
13. Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen-regulated genes.
Gregory CW; Hamil KG; Kim D; Hall SH; Pretlow TG; Mohler JL; French FS
Cancer Res; 1998 Dec; 58(24):5718-24. PubMed ID: 9865729
[TBL] [Abstract][Full Text] [Related]
14. Differential androgen receptor signals in different cells explain why androgen-deprivation therapy of prostate cancer fails.
Niu Y; Chang TM; Yeh S; Ma WL; Wang YZ; Chang C
Oncogene; 2010 Jun; 29(25):3593-604. PubMed ID: 20440270
[TBL] [Abstract][Full Text] [Related]
15. Estrogen induces androgen-repressed SOX4 expression to promote progression of prostate cancer cells.
Yang M; Wang J; Wang L; Shen C; Su B; Qi M; Hu J; Gao W; Tan W; Han B
Prostate; 2015 Sep; 75(13):1363-75. PubMed ID: 26015225
[TBL] [Abstract][Full Text] [Related]
16. Androgen action in the prostate gland.
Yadav N; Heemers HV
Minerva Urol Nefrol; 2012 Mar; 64(1):35-49. PubMed ID: 22402316
[TBL] [Abstract][Full Text] [Related]
17. Altered corepressor SMRT expression and recruitment to target genes as a mechanism that change the response to androgens in prostate cancer progression.
Godoy AS; Sotomayor PC; Villagran M; Yacoub R; Montecinos VP; McNerney EM; Moser M; Foster BA; Onate SA
Biochem Biophys Res Commun; 2012 Jul; 423(3):564-70. PubMed ID: 22695118
[TBL] [Abstract][Full Text] [Related]
18. Identification of a clinically relevant androgen-dependent gene signature in prostate cancer.
Heemers HV; Schmidt LJ; Sun Z; Regan KM; Anderson SK; Duncan K; Wang D; Liu S; Ballman KV; Tindall DJ
Cancer Res; 2011 Mar; 71(5):1978-88. PubMed ID: 21324924
[TBL] [Abstract][Full Text] [Related]
19. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
[TBL] [Abstract][Full Text] [Related]
20. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen.
Gregory CW; Johnson RT; Mohler JL; French FS; Wilson EM
Cancer Res; 2001 Apr; 61(7):2892-8. PubMed ID: 11306464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
